Neuroscience News and Research

RSS

Jefferson experts review most commonly used CAM practices for mood disorders

Mood disorders are among the most prevalent mental health issues today. While medication is available, more and more people are turning to complementary and alternative medicine (CAM), including herbal remedies, acupuncture, and meditation to help manage their mood disorders.

22 Sep 2011

Wnt signaling pathway plays an important role in early-onset dementia

No cure exists for frontotemporal dementia, which strikes between the ages of 40 and 64 and accounts for at least one in four cases of early-onset dementia. Caused by the death of cells in the front and sides of the brain, the disease can lead to dramatic changes in a patient's personality and behavior, including the loss of the ability to communicate.

22 Sep 2011

Common genetic variants linked to schizophrenia and bipolar disorder

Knowledge about the biological origin of diseases like schizophrenia, bipolar disorder and other psychiatric conditions is critical to improving diagnosis and treatment.

22 Sep 2011

Advertisements seduce consumers to buy products

Are you wooed by advertising? Of course you are. After all, it's one thing to go out and buy a new washing machine after the old one exploded, quite another to impulse-buy that 246-inch flat screen TV that just maybe, in hindsight, you didn't really need.

21 Sep 2011

Saladax, Bristol-Myers Squibb expand Alzheimer's diagnostic assays agreement

Bristol-Myers Squibb Company and Saladax Biomedical, Inc., announced today they have expanded their multi-year agreement covering the development and commercialization of diagnostic assays for the early detection of Alzheimer's disease to include Ortho-Clinical Diagnostics, Inc.

21 Sep 2011

Long-term immunosuppressants improve survival for lupus patients with ESKD

Researchers at Albert Einstein College of Medicine of Yeshiva University have shown that close supervision by rheumatologists and the use of immunosuppressant drugs improve the survival of lupus patients with end-stage kidney disease—a finding that could reverse long-standing clinical practice.

21 Sep 2011

Free public lecture to reveal new insights into brain cells linked with stroke, cerebral palsy

A free public lecture at the University of Leicester is to discuss how the white matter of the brain could be the key to understanding and treating brain disorders - not grey matter as previously thought.

21 Sep 2011

NIH to honor two Scripps Research scientists with innovator awards

Two Scripps Research Institute scientists have won prestigious National Institutes of Health (NIH) Director's New Innovator Awards. The recipients are Assistant Professor Michael Petrascheck of the institute's La Jolla, California campus, and Assistant Professor Brian Paegel of the Jupiter, Florida campus.

21 Sep 2011

Researchers’ discovery may revolutionize treatment of Lou Gehrig’s disease

A team of researchers from the University of British Columbia and the Vancouver Coastal Health Research Institute have found a key link between prions and the neurodegenerative disease ALS (Amyotrophic Lateral Sclerosis), also known as Lou Gehrig’s disease. The discovery is significant as it opens the door to novel approaches to the treatment of ALS.

20 Sep 2011

Yawning could regulate brain temperature

A study led by Andrew Gallup, a postdoctoral research associate in Princeton University's Department of Ecology and Evolutionary Biology, is the first involving humans to show that yawning frequency varies with the season and that people are less likely to yawn when the heat outdoors exceeds body temperature.

20 Sep 2011

People with diabetes more likely to develop dementia

People with diabetes appear to be at a significantly increased risk of developing dementia, according to a study published in the September 20, 2011, print issue of Neurology, the medical journal of the American Academy of Neurology.

20 Sep 2011

SK Biopharmaceuticals, Mayo Clinic collaborate to develop new treatments for ALS

Mayo Clinic's campus in Florida has entered into a collaborative and sponsored research agreement with SK Biopharmaceuticals of Seoul, South Korea, with the goal of developing new treatments for amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease. The collaboration marks a new approach to combating a disease that has proved difficult to treat in recent clinical trials.

20 Sep 2011

Mayo Clinic, SK biopharmaceuticals collaborate to discover new ALS drugs

South Korean biotech SK biopharmaceuticals announced yesterday that they signed an agreement to collaborate with the Mayo Clinic for the discovery of new drugs targeting Amyotrophic Lateral Sclerosis.

20 Sep 2011

Landmark international study confirms common genetic contribution to mental illness

An international research consortium has confirmed that common genetic variants contribute to a person’s risk of schizophrenia and bipolar disorder. The largest study of its kind provides new molecular evidence that 11 regions have strong association with these diseases, including six regions not previously observed. The researchers also found that many of these DNA variations contribute to both diseases. The findings, reported by the Psychiatric Genome-Wide Association Study Consortium (PGC) and published online in two papers in the journal Nature Genetics, represent significant advances in the understanding the causes of these severe and often debilitating disorders.

18 Sep 2011

Reducing levels of protein FKBP51 may yield new antidepressant therapies

Decreasing expression of a protein associated with susceptibility to depression made old mice resistant to depressive-like behavior while improving their hormonal response to stress, a study led by researchers at the University of South Florida found. The lack of this protein, FKBP51, did not adversely affect their memory, learning, or basic motor functions.

17 Sep 2011

Elan commences planned measures to reduce indebtedness

Elan Corporation, plc announced today that it has commenced planned measures to reduce its indebtedness using the cash proceeds received in connection with the combination of its EDT business with Alkermes Inc., which closed today.

17 Sep 2011

Alkermes completes merger with Elan Drug Technologies

Alkermes plc and Elan Corporation, plc today announced the completion of the merger between Alkermes, Inc. and Elan Drug Technologies (EDT), the drug formulation and manufacturing business unit of Elan, following the approval of the merger by Alkermes, Inc. shareholders on Sept. 8, 2011.

17 Sep 2011

ONGLYZA used with insulin maintains improvement in glucose control in adults with type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced results from an investigational Phase 3b clinical study in which the addition of ONGLYZA (saxagliptin) 5 mg to ongoing insulin therapy (with or without metformin) maintained reductions of blood sugar levels (glycosylated hemoglobin levels, or HbA1c) in adult patients with type 2 diabetes compared to the addition of placebo (with or without metformin) from 24 to 52 weeks.

16 Sep 2011

Anavex announces ANAVEX pre-clinical data on Alzheimer's disease

Anavex Life Sciences Corp. will present the most recent data showing the therapeutic potential of ANAVEX compounds in animal models of Alzheimer's disease at a special symposium of the 34th annual meeting of the Japan Neuroscience Society.

16 Sep 2011

Researchers discuss how decision neuroscience hopes to advance understanding of brain

Although still a young field, research in "decision neuroscience" has exploded in the last decade, with scientists beginning to decipher what exactly is happening in our brains when we are making choices, whether big or small.

16 Sep 2011